deferiprone has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In summary, deferiprone induced declines in proliferative responses at a dosage that is within peak serum pharmacological concentrations." | 1.37 | Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects. ( Benedict, SH; Garcia, SL; LeVine, SM; Lynch, SG; Rues, L; Slusser, JG; Sweeney, ME, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sweeney, ME | 1 |
| Slusser, JG | 1 |
| Lynch, SG | 1 |
| Benedict, SH | 1 |
| Garcia, SL | 1 |
| Rues, L | 1 |
| LeVine, SM | 1 |
1 other study available for deferiprone and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.
Topics: Adjuvants, Immunologic; Adult; Case-Control Studies; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8- | 2011 |